**Indication** | Anxiety  
--- | ---  
**INN** | Diazepam  
**Medicine type** | Chemical agent  
**List type** | Core  
**Additional notes** | For short-term emergency management of acute and severe anxiety symptoms only  
**Formulations** | Oral > Solid: 5 mg (scored); 2 mg (scored)  
**EML status history** | First added in 1977 (TRS 615)  
Changed in 1979 (TRS 641)  
Changed in 1991 (TRS 825)  
Changed in 1993 (TRS 850)  
Changed in 2007 (TRS 950)  
Changed in 2021 (TRS 1035)  
Changed in 2023 (TRS 1049)  
**Sex** | All  
**Age** | Adolescents and adults  
**Therapeutic alternatives** | Lorazepam (ATC codes: N05BA06)  
**Patent information** | Patents have expired in most jurisdictions  
*Read more about patents.*  
**Wikipedia** | [Diazepam](https://en.wikipedia.org/wiki/Diazepam)  
**DrugBank** | [Diazepam](https://www.drugbank.ca/substance/D000005)  

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of a note to the listing of diazepam in this section of the EML to indicate use is only recommended for the short-term emergency management of acute and severe anxiety symptoms as the balance of benefits and risks of diazepam use under these circumstances is considered favourable. The Committee also recommended that lorazepam should be specified as the only therapeutic alternative under the square box listing for diazepam for this indication. These recommendations are aligned with expected recommendations in updated mhGAP guidelines.